Cath Lab Clinical Trial Study Cardiovascular Surgery

National Institutes of Health researchers have identified a biological pathway that contributes to the high rate of vein graft failure following bypass surgery. Using mouse models of bypass surgery, they showed that excess signaling via the transforming growth factor beta (TGF-Beta) family causes the inner walls of the vein become too thick. This slows down or sometimes even blocks the blood flow that the graft was intended to restore. Inhibition of the TGF-B signaling pathway reduced overgrowth in the grafted veins.

Boston Scientific Corp. received CE marking for the Rebel Platinum Chromium Coronary Stent System, the company's latest generation bare metal stent for the treatment of coronary artery disease (CAD).

Janssen Research & Development LLC (Janssen) announced the U.S. Food and Drug Administration (FDA) issued complete response letters (CRLs) regarding supplemental New Drug Applications (sNDAs) for the use of rivaroxaban, an oral anticoagulant, to reduce the risk of secondary cardiovascular events — defined as heart attack, stroke or death — in patients with acute coronary syndrome (ACS) and to reduce the risk of stent thrombosis in the same population, in combination with standard antiplatelet therapy.

Privately held On-X Life Technologies Inc. (On-X LTI) launched its European marketing campaign for the On-X Plus 1.5 Aortic Heart Valve in concert with its Great Britain distributor Vascutek Corp. at the Annual Meeting & Cardiothoracic Forum of the Society for Cardiothoracic Surgery in Great Britain & Ireland, March 10-12, Edinburgh, Scotland.

 

Micell Technologies Inc. announced that imaging and clinical results from the DESSOLVE I and DESSOLVE II trials of its MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES) were presented at the 25th Annual Transcatheter Cardiovascular Therapeutics (TCT) Conference held in San Francisco, Oct. 27 to Nov. 1, 2013. 

Houston Healthcare is putting patient safety first by offering low dose computed tomography (CT) exams with the industry’s best solutions and a comprehensive dose management approach from Toshiba America Medical Systems Inc. 

iRhythm Technologies Inc., a healthcare information services company, announced that new study data support the use of its ZIO Service to help identify underlying cardiac arrhythmias in patients who have had a stroke or transient ischemic attack (TIA). 

The U.S. Food and Drug Administration (FDA) cleared Toshiba’s CT Myocardial Perfusion capability. Available on Toshiba’s Aquilion One and Aquilion OneVison Edition CT systems, Myocardial Perfusion allows clinicians to visualize myocardial ischemia with CT, providing a clinical and operational solution to make work flow.

McKesson announced a cardiology solution called Qualitative Intelligence and Communication System (QICS). QICS for cardiology helps organizations automate and manage cardiology workflows to promote efficiency and effectiveness. The solution offers integrated workflows and results communications management within the cardiovascular information system (CVIS).

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now